Journal: Materials Today Bio
Article Title: A MnO 2 -based tumor-seeking nanoplatform for enhanced chemoimmunotherapy against 4T1 breast cancer
doi: 10.1016/j.mtbio.2025.102000
Figure Lengend Snippet: In vitro BMDC Maturity and BMDM Repolarization Assay. Representative flow cytometry graph of CD80 + CD86 + cells in BMDCs after treated with normal saline (A), PTX injections (B), Squ@APS-IR820 NPs (C), MnO 2 @APS-IR820 NPs (D), Squ@APS NPs + MnO 2 @APS NPs (E), and Squ@APS-IR820 NPs + MnO 2 @APS-IR820 NPs (F). Percentages of CD80 + CD86 + cells (G). Flow cytometry chart of CD86 + CD206 - cells (H–M) and quantification of the proportion (N) of CD86 + CD206 - BMDMs after being incubated with different treatments (n = 3). Differences among groups were calculated by one-way ANOVA analysis. ∗ p < 0.05, ∗∗ p < 0.01, and ∗∗∗ p < 0.001. ns, no significance.
Article Snippet: Antibody: Anti-mouse CD16/32 Antibody was provided by Elabscience Biotechnology Co., Ltd, Anti-mouse CD11c PE, anti-mouse CD80 FITC, anti-mouse CD86 APC, anti-mouse CD86-PE, anti-mouse CD45-APC was purchased from Proteintech Group, Inc (Hubei, China).
Techniques: In Vitro, Flow Cytometry, Saline, Incubation